Eastman Chemical (NYSE: EMN) reported earnings on Oct. 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Eastman Chemical missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share dropped.

Gross margins were steady, operating margins shrank, net margins dropped.

Revenue details
 Eastman Chemical booked revenue of $2.26 billion. The 10 analysts polled by S&P Capital IQ expected sales of $2.36 billion on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $1.81 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.57. The 14 earnings estimates compiled by S&P Capital IQ anticipated $1.42 per share. GAAP EPS of $0.99 for Q3 were 15% lower than the prior-year quarter's $1.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 23.2%, about the same as the prior-year quarter. Operating margin was 13.3%, 120 basis points worse than the prior-year quarter. Net margin was 6.8%, 230 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $2.31 billion. On the bottom line, the average EPS estimate is $1.22.

Next year's average estimate for revenue is $8.32 billion. The average EPS estimate is $5.26.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 181 members out of 206 rating the stock outperform, and 25 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give Eastman Chemical a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eastman Chemical is outperform, with an average price target of $61.14.